JPH10502388A - 経皮ドラッグデリバリーシステム - Google Patents
経皮ドラッグデリバリーシステムInfo
- Publication number
- JPH10502388A JPH10502388A JP8504133A JP50413396A JPH10502388A JP H10502388 A JPH10502388 A JP H10502388A JP 8504133 A JP8504133 A JP 8504133A JP 50413396 A JP50413396 A JP 50413396A JP H10502388 A JPH10502388 A JP H10502388A
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- drug
- transdermal
- cyclodextrin
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.少なくとも1つの治療剤を供給するための制御された放出経皮システムであ って、 (a)イオン化された形態の治療剤および (b)水を吸収すると緩衝溶液に変換するpH調整剤および (c)シクロデキストリン、シクロデキストリン誘導体およびシクロデキスト リンポリマーよりなる群から選ばれた環状化された多糖であって、該環状化され た多糖が治療剤と包接錯体を形成することにより、緩衝液における治療剤の溶解 度を改善することが可能となる環状化された多糖 からなる貯蔵部ならびに イオン化された形態のまたは包接錯体の治療剤を実質的に透過させないが、水お よびイオン化されていない治療剤を実質的に透過させるポリマーからなる貯蔵壁 からなる経皮システム。 2.シクロデキストリン誘導体が2−ヒドロキシプロピル−β−シクロデキスト リンまたは2−ヒドロキシプロピル−γ−シクロデキストリンである請求の範囲 第1項記載の経皮システム。 3.治療剤がデキサメデトミジンである請求の範囲第1項または第2項記載の経 皮システム。 4.貯蔵壁に含まれるポリマーがエラストマー型ポリマーである請求の範囲第1 項、第2項または第3項記載の経皮システム。 5.エラストマー型ポリマーが、シリコーンポリマー類、 ポリイソブチレンおよびシリコーンポリエチレンオキシドの共重合体類よりなる 群から選ばれたポリマーである請求の範囲第4項記載の経皮システム。 6.貯蔵部が、治療剤、環状化した多糖およびpH調整剤を含む1つのコアから なる請求の範囲第1項、第2項または第3項記載の経皮システム。 7.貯蔵部が複数の個々のコアからなり、各コアが治療剤、環状化した多糖およ びpH調整剤を含む請求の範囲第1項、第2項または第3項記載の経皮システム 。 8.システムが貯蔵壁としてポリマー・マトリックスを含み、該マトリックスに 複数の個々のコアが含まれる請求の範囲第1項、第2項または第3項記載の経皮 システム。 9.システムが貯蔵壁としてポリマー・メンブレンを含む請求の範囲第1項、第 2項または第3項記載の経皮システム。 10.貯蔵壁が治療剤で充填される請求の範囲第1項から第6項までのいずれかま たは第9項記載の経皮システム。 11.システムがさらに、治療剤で充填される、速度を限定するポリマー・メンブ レンからなる請求の範囲第1項から第7項までのいずれかに記載の経皮システム 。 12.治療剤とpH調整剤と環状化された多糖の貯蔵部を作成することならびにこ れを貯蔵壁に接触させて置くことからなる請求の範囲第1項から第11項までの いずれかに記載のシステムの製造法。 13.請求の範囲第1項の制御された放出経皮システムを患者に投与することから なる経皮ドラッグデリバリー の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9413866A GB2290964A (en) | 1994-07-08 | 1994-07-08 | Transdermal drug delivery system |
GB9413866.6 | 1994-07-08 | ||
PCT/FI1995/000358 WO1996001626A1 (en) | 1994-07-08 | 1995-06-20 | Transdermal drug delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10502388A true JPH10502388A (ja) | 1998-03-03 |
JP3734267B2 JP3734267B2 (ja) | 2006-01-11 |
Family
ID=10758074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50413396A Expired - Lifetime JP3734267B2 (ja) | 1994-07-08 | 1995-06-20 | 経皮ドラッグデリバリーシステム |
Country Status (12)
Country | Link |
---|---|
US (1) | US5817332A (ja) |
EP (1) | EP0764020B1 (ja) |
JP (1) | JP3734267B2 (ja) |
AT (1) | ATE178485T1 (ja) |
AU (1) | AU2740595A (ja) |
CA (1) | CA2193129C (ja) |
DE (1) | DE69508938T2 (ja) |
DK (1) | DK0764020T3 (ja) |
ES (1) | ES2130622T3 (ja) |
GB (1) | GB2290964A (ja) |
GR (1) | GR3030369T3 (ja) |
WO (1) | WO1996001626A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919527B2 (en) | 2002-02-25 | 2011-04-05 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
US8030350B2 (en) | 2005-02-24 | 2011-10-04 | Diffusion Pharmaceuticals Llc | Trans carotenoids, their synthesis, formulation and uses |
US8206751B2 (en) | 2007-10-31 | 2012-06-26 | Diffusion Pharmaceuticals Llc | Class of therapeutics that enhance small molecule diffusion |
US8269027B2 (en) | 2002-02-25 | 2012-09-18 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
US8293804B2 (en) | 2007-04-13 | 2012-10-23 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
US8974822B2 (en) | 2010-06-02 | 2015-03-10 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
JP2017501224A (ja) * | 2013-12-18 | 2017-01-12 | ジー・エヌ・ティー・エル・エル・シー | 緑内障の治療用組成物及び方法 |
US10130689B2 (en) | 2009-06-22 | 2018-11-20 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
US11185523B2 (en) | 2016-03-24 | 2021-11-30 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19980033113A (ko) * | 1996-10-25 | 1998-07-25 | 야스다케 히지 | 국소 마취제 수용액, 국소 마취제의 용해도를 개선시키는 방법, 신경독성이 감소된 국소 마취제 및 국소 마취제의 신경 독성을 감소시키는 방법 |
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
DE19810951B4 (de) * | 1998-03-13 | 2005-09-29 | Ciba Speciality Chemicals Holding Inc. | Verwendung eines textilen Materials als transdermales Abgabesystem sowie Verfahren zu seiner Herstellung |
DE19814087A1 (de) * | 1998-03-30 | 1999-10-14 | Lohmann Therapie Syst Lts | Feuchtigkeitsaktivierbares therapeutisches System |
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
US6719997B2 (en) | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
ES2239057T3 (es) * | 1999-12-16 | 2005-09-16 | Dermatrends, Inc. | Agentes de liberacion de hidroxido utilizados como potenciadores de la permeacion cutanea. |
US20030104041A1 (en) * | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
US6673363B2 (en) | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6689378B1 (en) | 1999-12-28 | 2004-02-10 | Kimberly-Clark Worldwide, Inc. | Cyclodextrins covalently bound to polysaccharides |
US7179483B2 (en) | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
US6878693B2 (en) | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
DK1629844T4 (da) | 2004-07-13 | 2012-05-29 | Bayer Schering Pharma Oy | Retarderet indgivelsessystem med kontrolleret initialudbrud |
WO2006135785A2 (en) * | 2005-06-10 | 2006-12-21 | Medical College Of Georgia Research Institute | Compositions and methods for treating immune disorders |
US9446017B2 (en) | 2005-08-11 | 2016-09-20 | Augusta University Research Institute, Inc. | Compositions and methods for treating herpes simplex virus |
WO2007117923A2 (en) * | 2006-04-07 | 2007-10-18 | Allergan, Inc. | Compositions including relatively water insoluble/unwettable drugs and methods for using same |
US9114133B2 (en) | 2006-08-25 | 2015-08-25 | U.S. Dept. Of Veterans Affairs | Method of improving diastolic dysfunction |
WO2011014775A1 (en) | 2009-07-31 | 2011-02-03 | The Brigham And Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
EP2556082B1 (en) | 2010-04-08 | 2017-02-22 | Emory University | Substituted androst-4-ene diones |
CA2830069C (en) | 2011-03-20 | 2019-11-12 | The University Of British Columbia | Therapeutic agent for emphysema and copd |
EP2704726B1 (en) | 2011-05-04 | 2018-10-31 | Trustees of Boston University | Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
EP2543370A1 (en) | 2011-07-06 | 2013-01-09 | Georgia Health Sciences University Research Institute, Inc. | Compositions and Methods for Treating Herpes Simplex Virus |
WO2013071049A1 (en) | 2011-11-10 | 2013-05-16 | Trustees Of Boston College | Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity |
WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
EP3036226B1 (en) | 2013-08-22 | 2020-01-08 | The General Hospital Corporation | Inhibitors of human 12/15-lipoxygenase |
WO2015031765A2 (en) | 2013-08-29 | 2015-03-05 | Trustees Of Boston University | Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections |
KR101831290B1 (ko) | 2013-10-07 | 2018-02-22 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물 |
CA2924188C (en) * | 2013-10-07 | 2018-12-18 | Teikoku Pharma Usa, Inc. | Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions |
ES2847936T3 (es) | 2013-10-07 | 2021-08-04 | Teikoku Pharma Usa Inc | Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina |
TWI704933B (zh) | 2013-10-07 | 2020-09-21 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
US9974754B2 (en) | 2013-12-18 | 2018-05-22 | Maruishi Pharmaceutical Co., Ltd. | Hydrous adhesive patch |
EP3303286B1 (en) | 2015-06-01 | 2023-10-04 | Cedars-Sinai Medical Center | Compounds that bind to rela of nf-kb for use in treating cancer |
WO2017017631A2 (en) | 2015-07-28 | 2017-02-02 | Vyome Biosciences Pvt. Ltd. | Antibacterial therapeutics and prophylactics |
US10493049B2 (en) | 2016-02-10 | 2019-12-03 | Niracle LLC | Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations |
BR112019013503A2 (pt) | 2016-12-31 | 2020-01-07 | Bioxcel Therapeutics, Inc. | Uso de dexmedetomidina sublingual para o tratamento da agitação |
CN114983981A (zh) | 2018-06-27 | 2022-09-02 | 比奥克斯塞尔医疗股份有限公司 | 含右美托咪定的膜制剂及其制造方法 |
TWI772807B (zh) | 2019-05-27 | 2022-08-01 | 日商救急藥品工業股份有限公司 | 外用製劑 |
MX2022000709A (es) | 2019-07-19 | 2022-05-19 | Bioxcel Therapeutics Inc | Regimenes de tratamiento con dexmedetomidina no sedante. |
CN117545474A (zh) | 2021-11-08 | 2024-02-09 | 李维庸 | 一种用于向患者递送药物的透皮给药系统 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4756710A (en) * | 1985-04-05 | 1988-07-12 | Merck & Co., Inc. | pH-Mediated drug delivery system |
EP0241806A1 (en) * | 1986-04-14 | 1987-10-21 | Fujisawa Pharmaceutical Co., Ltd. | Sustained-release transdermal delivery preparations |
US4781924A (en) * | 1987-11-09 | 1988-11-01 | Alza Corporation | Transdermal drug delivery device |
SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
HU210921B (en) * | 1990-03-28 | 1995-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them |
GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
GB9111732D0 (en) * | 1991-05-31 | 1991-07-24 | Orion Yhtymae Oy | The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs |
WO1993007858A1 (en) * | 1991-10-16 | 1993-04-29 | Arto Olavi Urtti | Peroral drug delivery system |
US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
-
1994
- 1994-07-08 GB GB9413866A patent/GB2290964A/en not_active Withdrawn
-
1995
- 1995-06-20 DK DK95922554T patent/DK0764020T3/da active
- 1995-06-20 ES ES95922554T patent/ES2130622T3/es not_active Expired - Lifetime
- 1995-06-20 DE DE69508938T patent/DE69508938T2/de not_active Expired - Lifetime
- 1995-06-20 US US08/765,766 patent/US5817332A/en not_active Expired - Lifetime
- 1995-06-20 WO PCT/FI1995/000358 patent/WO1996001626A1/en active IP Right Grant
- 1995-06-20 CA CA002193129A patent/CA2193129C/en not_active Expired - Lifetime
- 1995-06-20 EP EP95922554A patent/EP0764020B1/en not_active Expired - Lifetime
- 1995-06-20 AU AU27405/95A patent/AU2740595A/en not_active Abandoned
- 1995-06-20 AT AT95922554T patent/ATE178485T1/de active
- 1995-06-20 JP JP50413396A patent/JP3734267B2/ja not_active Expired - Lifetime
-
1999
- 1999-05-28 GR GR990401461T patent/GR3030369T3/el unknown
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8269027B2 (en) | 2002-02-25 | 2012-09-18 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
US9604899B2 (en) | 2002-02-25 | 2017-03-28 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
US7919527B2 (en) | 2002-02-25 | 2011-04-05 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
JP2015108001A (ja) * | 2005-02-24 | 2015-06-11 | ディフュージョン・ファーマシューティカルズ・エルエルシー | トランスカロテノイド、それらの合成、配合、および使用 |
JP2012051896A (ja) * | 2005-02-24 | 2012-03-15 | Diffusion Pharmaceuticals Llc | トランスカロテノイド、それらの合成、配合、および使用 |
US11278621B2 (en) | 2005-02-24 | 2022-03-22 | Diffusion Pharmaceuticals Llc | Trans carotenoids, their synthesis, formulation and uses |
JP2017048205A (ja) * | 2005-02-24 | 2017-03-09 | ディフュージョン・ファーマシューティカルズ・エルエルシー | トランスカロテノイド、それらの合成、配合、および使用 |
US8030350B2 (en) | 2005-02-24 | 2011-10-04 | Diffusion Pharmaceuticals Llc | Trans carotenoids, their synthesis, formulation and uses |
US9950067B2 (en) | 2005-02-24 | 2018-04-24 | Diffusion Pharmaceuticals, LLC | Trans carotenoids, their synthesis, formulation and uses |
US8293804B2 (en) | 2007-04-13 | 2012-10-23 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
US8901174B2 (en) | 2007-04-13 | 2014-12-02 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
US8206751B2 (en) | 2007-10-31 | 2012-06-26 | Diffusion Pharmaceuticals Llc | Class of therapeutics that enhance small molecule diffusion |
US10130689B2 (en) | 2009-06-22 | 2018-11-20 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
US11147859B2 (en) | 2009-06-22 | 2021-10-19 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
US8974822B2 (en) | 2010-06-02 | 2015-03-10 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
US10016384B2 (en) | 2010-06-02 | 2018-07-10 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
US11491129B2 (en) | 2010-06-02 | 2022-11-08 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
JP2017501224A (ja) * | 2013-12-18 | 2017-01-12 | ジー・エヌ・ティー・エル・エル・シー | 緑内障の治療用組成物及び方法 |
US11185523B2 (en) | 2016-03-24 | 2021-11-30 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
CA2193129A1 (en) | 1996-01-25 |
US5817332A (en) | 1998-10-06 |
CA2193129C (en) | 2007-11-06 |
GB2290964A (en) | 1996-01-17 |
GR3030369T3 (en) | 1999-09-30 |
EP0764020B1 (en) | 1999-04-07 |
DE69508938T2 (de) | 1999-09-16 |
WO1996001626A1 (en) | 1996-01-25 |
EP0764020A1 (en) | 1997-03-26 |
GB9413866D0 (en) | 1994-08-24 |
DK0764020T3 (da) | 1999-10-18 |
ATE178485T1 (de) | 1999-04-15 |
DE69508938D1 (de) | 1999-05-12 |
ES2130622T3 (es) | 1999-07-01 |
AU2740595A (en) | 1996-02-09 |
JP3734267B2 (ja) | 2006-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3734267B2 (ja) | 経皮ドラッグデリバリーシステム | |
US10596126B2 (en) | Transdermal therapeutic system comprising active ingredient particles and having increased active ingredient flux | |
US5120546A (en) | Transdermal system | |
JP2511472B2 (ja) | 速度コントロ―ル接着剤を有する改良された経皮投与デバイス | |
Kim et al. | Polymeric drug delivery systems | |
Jantzen et al. | Sustained-and controlled-release drug delivery systems | |
US5378730A (en) | Permeation enhancer comprising ethanol and monoglycerides | |
JP4599498B2 (ja) | 非ポリマー持続性解離供給システム | |
JP4881861B2 (ja) | デリバリーシステム | |
JPS61238721A (ja) | 活性物質の放出がコントロ−ルされた単位投与形態 | |
Chien | Pharmaceutical considerations of transdermal nitroglycerin delivery: the various approaches | |
Jain et al. | Development and characterization of transdermal drug delivery systems for diltiazem hydrochloride | |
HUT74865A (en) | Transdermal therapeutic systems for the administration of serotonin agonists | |
Varshosaz et al. | Development and physical characterization of a periodontal bioadhesive gel of metronidazole | |
Vasil'ev et al. | Transdermal therapeutic systems for controlled drug release (a review) | |
CZ299086B6 (cs) | Dermální aplikacní systém a zpusob jeho výroby | |
JPS63501289A (ja) | リポソ−ム経皮薬剤供給系 | |
Laurencin et al. | Polymeric controlled release systems: new methods for drug delivery | |
JPH07500110A (ja) | 経口的ドラッグデリバリーシステム | |
Tavano | Liposomal gels in enhancing skin delivery of drugs | |
Banker et al. | Sustained-and Controlled-Release Drug-Delivery Systems | |
Lee et al. | Percutaneous absorption and model membrane variations of melatonin in aqueous-based propylene glycol and 2-hydroxypropyl-β-cyclodextrin vehicles | |
Kobayashi et al. | In vitro/in vivo difference in enhanced skin permeation of nicardipine hydrochloride by the 1-menthol-ethanol system | |
Hadžiabdić et al. | Transdermal Patches as Noninvasive Drug Delivery Systems | |
Heller | The use of polymers in the construction of controlled-release devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051011 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051018 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091028 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101028 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101028 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111028 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111028 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121028 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121028 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131028 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |